Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity
Chair, Javier Morales, MD, FACP, FACE, Juan Pablo Frías, MD, and Donna H. Ryan, MD, FTOS, discuss T2DM and obesity in this CME activity titled “Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity.” For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KZF865. CME credit will be available until May 7, 2023.
▶︎
Are We Using GLP-1 Medications All Wrong? with Dr. Ben Bikman
▶︎
The Biological Cost of Ozempic and Other GLP-1s
▶︎
The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management
▶︎
I'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs.
▶︎
Serena Williams and Oprah on Deciding to Take GLP-1 Medications
▶︎
150: Why Tirzepatide Works Better Than GLP-1 Alone
▶︎
GLP-1 Receptor Agonists After Bariatric Surgery How and When
▶︎
GLP 1 Deep Dive with Dr. Jeff Bland
▶︎
I’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.
▶︎
GLP-1 and the CNS Regulation of Appetite - Scott Kanoski, PhD
▶︎
Microdosing GLP-1: A New Approach to Inflammation-Driven Diseases | Empowering Midlife Wellness
▶︎
Ep:258 INSULIN RESISTANCE AND GLP1 MEDICATIONS - A WONDERDRUG? by Robert Cywes
▶︎
The Truth About GLP-1 Maintenance No One is Talking About | Docs Who Lifts
▶︎
GLP 1, Mounjaro, Wegovy & Ozempic: How These Affect Weight Loss & Metabolic Health | Dr. Rob Lustig
▶︎
Ozempic & Mounjaro: Same Shot. Opposite Results.
▶︎
How Do Ozempic, Mounjaro & Other GPL-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
▶︎
Why GLP-1 Feels Different at 1, 3, and 6 Months (Obesity Doctor)
▶︎
Oprah and Yale Researcher Break Down How Weight Loss Drugs Affect the Brain
▶︎
EFL021 - Metabolic Effects of a Dual GIP and GLP-1 RA
▶︎